Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03643575
Recruitment Status : Completed
First Posted : August 23, 2018
Results First Posted : February 22, 2019
Last Update Posted : March 27, 2019
Sponsor:
Information provided by (Responsible Party):
Reckitt Benckiser LLC ( Reckitt Benckiser Inc. )

Brief Summary:
Characterize the relative pharmacokinetics (PK) of 3 marketed products containing guaifenesin

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: Vicks Cough Syrup for Chesty Coughs Drug: Robitussin Extra Strength Chest Congestion Drug: Organ-I- NR tablet Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase I, Open- Label, Randomized, Multiple-dose, 3-way Crossover Relative Bioavailability Study to Characterize the Pharmacokinetics of the 3 Marketed Products Containing 200 mg Guaifenesin Under Fasted Conditions in Normal Healthy Subjects.
Actual Study Start Date : June 30, 2009
Actual Primary Completion Date : July 16, 2009
Actual Study Completion Date : July 16, 2009

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Treatment A: Vicks Cough Syrup for Chesty Coughs
Vicks Cough immediate-release (IR) syrup 15 mL (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
Drug: Vicks Cough Syrup for Chesty Coughs
Vicks Cough Syrup for Chesty Coughs 15 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water

Experimental: Treatment B: Robitussin Extra Strength Chest Congestion
Robitussin Extra Strength Chest Congestion 5 ml (containing 200 mg guaifenesin) every 4 hours x 3 doses with 240 mL of water after an overnight fast
Drug: Robitussin Extra Strength Chest Congestion
Robitussin Extra Strength Chest Congestion 5 mL (containing 200 mg guaifenesin) IR syrup with 240 mL of water

Experimental: Treatment C: Organ-I- NR tablet
Organ-I- NR 200 mg guaifenesin tablet every 4 hours x 3 doses with 240 mL of water after an overnight fast
Drug: Organ-I- NR tablet
Organ-I- NR tablet (containing 200 mg guaifenesin) with 240 mL of water




Primary Outcome Measures :
  1. Maximum Observed Plasma Concentration (Cmax) of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    Pharmacokinetic Parameter Cmax is the Maximum observed plasma concentration.

  2. Maximum Measured Plasma Concentration at Steady State (Cmax,ss) of Guaifenesin Following the Third Dose [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    Pharmacokinetic Parameter Cmax,ss is the Maximum observed plasma concentration following the third dose.

  3. Observed Plasma Concentration at the End of Dosing Interval at Steady State (Cmin,ss) of Guaifenesin Following the Third Dose [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    Observed plasma concentration at the end of the dosing interval following the third dose (that is, 4 hours following the third dose).

  4. Average Plasma Concentration (Cav) of Guaifenesin Following the Third Dose [ Time Frame: 8, 8.5, 8.75, 9, 9.5, 10, 11 and 12 hours ]

    Average plasma concentration (Cav) following the third dose, calculated as AUC(8-12) divided by the dosing interval, 4.

    Cav is calculated as AUC(8-12) / dosing interval, 4


  5. Time to Maximum Observed Plasma Concentration (Tmax) of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    Pharmacokinetic Parameter Tmax is the time of the maximum observed plasma concentration.

  6. Time to Maximum Observed Plasma Concentration at Steady State (Tmax,ss) of Guaifenesin Following the Third Dose [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    Pharmacokinetic Parameter Tmax, ss is the time of the maximum observed plasma concentration following the third dose.

  7. Apparent First-order Terminal Elimination Half-life (T1/2) of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    T1/2 is the apparent first-order terminal elimination half-life, calculated as ln(2)/Kel.

  8. Apparent First-order Terminal Elimination Rate Constant (Kel) of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    Kel is the apparent first-order terminal elimination rate constant calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares (LS) regression analysis using the maximum number of points (e.g., 3 or more non-zero plasma concentrations) in the terminal log-linear phase.

  9. Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration [AUC(0-t)] of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    AUC(0-t) is the area under the plasma concentration versus time curve from time 0 to the time of the last measurable concentration, as calculated by the linear trapezoidal method.

  10. Area Under Plasma Concentration Versus Time Curve From Time 0 to Infinity [AUC(0-inf)] of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    AUC(0-inf) is the area under the plasma concentration versus time curve from time 0 to infinity, calculated as AUC(0-t) + Ct/Kel, where Ct was the last measurable concentration and Kel is the apparent first-order terminal elimination rate constant.

  11. Area Under Plasma Concentration Versus Time Curve From 0 to 4 Hours [AUC(0-4)] of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3 and 4 hours ]
    AUC(0-4) is the area under the plasma concentration versus time curve from time 0 to 4 hours post dose (relative to first dose), as calculated by the linear trapezoidal method.

  12. Area Under Plasma Concentration Versus Time Curve From Time 8 to 12 Hours [AUC(8-12)] of Guaifenesin [ Time Frame: 8, 8.5, 8.75, 9, 9.5, 10, 11 and 12 hours ]
    AUC(8-12) is the area under the plasma concentration versus time curve from time 8 to 12 hours postdose (relative to first dose), as calculated by the linear trapezoidal method.

  13. Area Under Plasma Concentration Curve Ratio (AUCR) of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    Pharmacokinetic Parameter AUCR is the Ratio of AUC(0-t) to AUC(0-inf). AUCR = AUC(0-t) / AUC(0-inf).

  14. Accumulation Index (AI) of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4 hours and 8, 8.5, 8.75, 9, 9.5, 10, 11, 12 hours ]
    AI is the accumulation index, calculated as AUC(8-12) / AUC(0-4).

  15. Degree of Fluctuation (DF) of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    DF is the Degree of Fluctuation Index, calculated as (Cmax,ss - Cmin,ss) / Cav.

  16. Peak Plasma Concentrations at Steady State (Swing) of Guaifenesin [ Time Frame: 0 (Pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 4.5, 4.75, 5, 5.5, 6, 7, 8, 8.5, 8.75, 9, 9.5, 10, 11, 12, 14 and 16 hours ]
    Pharmacokinetic Parameter Swing is Calculated as (Cmax,ss - Cmin,ss) / Cmin,ss.


Secondary Outcome Measures :
  1. Number of Participants With Adverse Events (AEs) [ Time Frame: Up to day 2 (Period 3) ]

    Intensity was determined by the Investigator. For symptomatic Adverse Events (AEs) the following definitions were applied.

    Mild = AE did not limit usual activities; subject may have experienced slight discomfort.

    Moderate = AE resulted in some limitation of usual activities; subject may have experienced significant discomfort.

    Severe = AE resulted in an inability to carry out usual activities; subject may have experienced intolerable discomfort/pain.

    Relationship to Investigational Medicinal Products (IMP)

    Unlikely = Slight, but remote, chance that AE was caused by IMP. Possible = Reasonable suspicion that the AE was caused by IMP. Probable = Most likely that AE was caused by IMP.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Males and/or females between the ages of 19 and 55 years, inclusive.
  2. Females of childbearing potential must be using one of the following acceptable birth control methods:

    1. Intra-uterine device in place for at least 3 months prior to Day 1 of Period 1 through 30 days beyond study completion;
    2. Barrier method (condom or diaphragm) with spermicide for at least 7 days prior to screening through 30 days beyond study completion;
    3. Stable hormonal contraceptive (e.g., oral, depo injection, transdermal patch, or vaginal ring) for at least 3 months prior to Day 1 of Period 1 through 30 days beyond completion of study;

    Abstinence is not an acceptable form of contraception; however, abstinent female subjects may be admitted to the study if they agree, and have signed a statement to the effect, that upon becoming sexually active, will use a condom with spermicide from screening through 30 days beyond completion of the study.

  3. Females of non-childbearing potential should be surgically sterile (bilateral tubal ligation with surgery at least 6 months prior to study or hysterectomy and/or bilateral oophorectomy at least 3 months prior to Day 1 of Period 1) or postmenopausal >2 years prior to Day 1 of Period 1. A follicle stimulating hormone (FSH) concentration >40 miU/mL must be obtained and recorded for any postmenopausal females.
  4. Good general health as determined by the Principal Investigator's (PI) review of medical history, physical examination, vital sign measurements, electrocardiogram (ECG), and clinical laboratory measures.
  5. Within 15% of ideal body weight (Table of 'Desirable Weights of Adults' Metropolitan Life Insurance Company, 1983).
  6. Non-tobacco users, who have not used nicotine or nicotine-containing products for at least 365 days prior to Day 1 of Period 1.
  7. Able to read, understand and sign the informed consent after the nature of the study has been explained.
  8. Negative urine screen for drugs of abuse and alcohol at screening and each check in.
  9. If female, negative finding on serum pregnancy test at screening and each check-in.

Exclusion Criteria:

  1. Clinically significant abnormalities detected by medical history, physical examination, vial sign measurements, ECG, or clinical laboratory findings (as determined by the PI/designee) including a hemoglobin value <12 g/dL at screening. If a subject's hemoglobin drops below 11.0 g/dL during the study, the subject may be dropped from the study at the discretion of the PI.
  2. Any disease or condition, which could impact absorption, distribution, metabolism, or elimination of the study drugs (as determined by the PI/designee).
  3. Alcoholism or medicinal product or drug abuse within the past two years or excessive alcohol consumption (more than 10 units per week) (one unit is defined as 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of spirits (i.e., 'hard' liquor such as gin, whiskey, or vodka, et. al.). The subject is not to experience tolerance, withdrawal, compulsive use, or substance related problems such as medical complications, disruption in social and family relationships, vocational or financial difficulties, or legal problems.
  4. Females who are pregnant or nursing.
  5. History of sensitivity reaction to guaifenesin.
  6. History of or intolerance to lactose.
  7. Receipt of an investigational drug within 30 days prior to Day 1 of Period 1.
  8. Abnormal diet (for whatever reason) during the 30 days prior to Day 1 of Period 1.
  9. Donation of blood or significant loss of blood within 56 days or plasma within 14 days prior to Day 1 of Period 1.
  10. Known or suspected use of illicit drugs.
  11. The use of any medication (with the exception of hormonal contraceptives for women of childbearing potential) for 14 days or 5 half-lives of the drug (whichever is longer) prior to Day 1 of Period 1, if not approved by Investigator.
  12. Test positive for Hepatitis B surface antigen, Hepatitis C antibodies, or HIV at Screening.
  13. Subjects who have participated in previous Reckitt Benckiser studies.

Layout table for additonal information
Responsible Party: Reckitt Benckiser Inc.
ClinicalTrials.gov Identifier: NCT03643575     History of Changes
Other Study ID Numbers: 2009-GGE-05
First Posted: August 23, 2018    Key Record Dates
Results First Posted: February 22, 2019
Last Update Posted: March 27, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Guaifenesin
Phenylpropanolamine
Chlorpheniramine, phenylpropanolamine drug combination
Expectorants
Respiratory System Agents
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Appetite Depressants
Anti-Obesity Agents
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Nasal Decongestants
Vasoconstrictor Agents